Rangaswamy Govindarajan
Professor
University of Arkansas for Medical Sciences
faculty
Internal Med, College of Medicine
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Rangaswamy Govindarajan's research focuses on the treatment and understanding of advanced cancers, with a particular emphasis on gastrointestinal cancers, sarcoma, and melanoma. His work investigates novel therapeutic strategies aimed at improving patient outcomes and quality of life.
Recent publications by Dr. Govindarajan explore the enhancement of immune responses in hepatocellular carcinoma through oncolytic viruses and immune checkpoint blockade. He has also examined the use of multimodal reprogramming of the tumor microenvironment and virotherapy to improve immunotherapy response in pancreatic cancer models. Additionally, his research includes preliminary efficacy trials of self-affirmation interventions for newly diagnosed advanced cancer patients and analyses of quality-of-life outcomes, highlighting the importance of individual differences in patient experiences.
Research Overview
Dr. Rangaswamy Govindarajan is a hematologist and medical oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS). He is also a Professor in the UAMS Department of Internal Medicine, Division of Hematology/Oncology.Dr. Govindarajan received his medical degree from Mysore Medical College at the University of Mysore in Mysore, India. He completed an internship in General Medicine, Surgery and Ob/GYN/Pediatrics at K.R. Hospital & Cheluvamba Hospital in Mysore, India. Dr. Govindarajan completed his medical training at UAMS, first with a residency in Internal Medicine and then, as a fellow in the Division of Hematology/Oncology. He is board certified in Internal Medicine, Hematology and Oncology and is a Diplomate of the American Board of Internal Medicine.Dr. Govindarajan is a member of the American Society of Hematology and the American Society of Clinical Oncology. His primary clinical and research interests are gastrointestinal cancers, sarcoma and melanoma.
Metrics
- h-index: 14
- Publications: 66
- Citations: 1,509
Selected Publications
- Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026) DOI
- An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer (2025) DOI
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025) DOI
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025) DOI
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024) DOI
Grants & Funding
- CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etopos NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B Principal Investigator
- A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combinatio Sanofi-Aventis Principal Investigator
- CTSU ECOG 2108, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cance NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group Principal Investigator
- UARK 2004-40: A Companion Protocol for Biomarker Development and Pharmacogenetic Analysis in Subjects Enrolled in Clinical Therapeutic Trials Using Pa Amgen, Inc. Principal Investigator
- A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bo Merck & Company, Inc. Principal Investigator
- RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TR NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B Principal Investigator
- No FP attached NIH/Nat. Cancer Institute - Pass Through: Eastern Cooperative Oncology Group Principal Investigator
- Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (CALGB 80803) NIH/Nat. Cancer Institute - Pass Through: Cancer and Leukemia Group B Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics